Investors Presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syschem India, a BSE-listed API and pharmaceutical intermediates manufacturer, shared strong 9M FY25-26 results with revenue up 164% to ₹40,631 lakhs (vs ₹24,748 lakhs in 9M FY24-25). EBITDA surged 312% and PAT grew 858%, with EBITDA margin improving from 0.85% to 2.8%. Export sales of ₹107.62 crore in 9M FY25-26 already exceeded the full FY24-25 export figure of ₹90.89 crore, while domestic sales reached ₹247.83 crore. The company highlighted its capacity expansion plan from current 4,200 TPA to 8,000 TPA, supported by a 6-acre land bank, and outlined ambitions to scale across 3 continents and 10+ countries with its portfolio of 7+ API SKUs.
Strong revenue and profit growth, combined with margin expansion and capacity doubling plans, signal a positive growth trajectory. However, margins remain thin (under 3% EBITDA) and PAT margin at 1.6%, so investors should weigh the growth story against profitability sustainability. The stock trades at a modest market cap of ~₹43.5 crore with promoter holding at 56.71%.